Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Viridian Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 124 | 132 | +8 |
| Shares | 50.2M | 60.1M | +9.99M (+19.9%) |
| Value | $769.9M | $1.31B | +$540.0M (+70.1%) |
New holders (25)
Institutions that held Viridian Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (17)
Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Ra Capital Management, L.P. | 2,007,946 | $30.8M |
| Artal Group S.A. | 504,978 | $7.75M |
| Point72 Asset Management, L.P. | 439,191 | $6.74M |
| PFM Health Sciences, LP | 360,830 | $5.54M |
| Twinbeech Capital LP | 94,005 | $1.44M |
| Connor, Clark & Lunn Investment Management Ltd. | 80,002 | $1.23M |
| AlphaCentric Advisors LLC | 80,000 | $1.23M |
| Jump Financial, LLC | 61,654 | $945.8K |
| Chartwell Investment Partners, LLC | 39,600 | $608.0K |
| Man Group plc | – | $581.4K |
| Davidson Kempner Capital Management LP | 23,857 | $366.0K |
| Dark Forest Capital Management LP | 17,223 | $264.2K |
| Engineers Gate Manager LP | 16,495 | $253.0K |
| Gsa Capital Partners LLP | 10,844 | $166.0K |
| Squarepoint Ops LLC | 10,519 | $161.4K |
| US Bancorp | 37 | $568 |
| CWM, LLC | 14 | $0 |